Back


19/11/2019
Orphazyme receives Breakthrough Therapy Designation for arimoclomol in Niemann-Pick Disease Type C (NPC)
Copenhagen, Denmark, November 19, 2019 – Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for arimoclomol, an investigational drug for the treatment of Niemann-Pick Disease Type C (NPC). [...]

Download the pdf file





X

X